Davis J M, Andriukaitis S
J Clin Psychopharmacol. 1986 Feb;6(1 Suppl):2S-10S.
The natural course of schizophrenia is poor; in the absence of consistently effective and broadly applied treatment, about two thirds of schizophrenic patients remain symptomatic. Antipsychotic drugs dramatically improve the prognosis of these patients, and there is limited evidence that the use of these drugs during an acute episode may improve a patient's long-term outcome. Continued administration of antipsychotic drugs significantly attenuates the relapse rate among schizophrenic patients; however, compliance with oral antipsychotic medication remains a problem in this population. Long-acting depot antipsychotic drugs have an obvious advantage in improving patient compliance, and there are some data that suggest that relapse rates may be lower in patients receiving depot drugs compared with oral drugs. Because of the greater assurance long-acting depot drugs provide about medication compliance, these drugs clearly have a significant role in the maintenance treatment of schizophrenic patients.
精神分裂症的自然病程不佳;在缺乏持续有效且广泛应用的治疗的情况下,约三分之二的精神分裂症患者仍有症状。抗精神病药物显著改善了这些患者的预后,并且有有限的证据表明在急性发作期间使用这些药物可能改善患者的长期结局。持续服用抗精神病药物可显著降低精神分裂症患者的复发率;然而,口服抗精神病药物的依从性在这一人群中仍然是个问题。长效注射用抗精神病药物在提高患者依从性方面具有明显优势,并且有一些数据表明,与口服药物相比,接受长效注射用药物治疗的患者复发率可能更低。由于长效注射用药物在药物依从性方面提供了更大的保障,这些药物在精神分裂症患者的维持治疗中显然具有重要作用。